<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57061">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960933</url>
  </required_header>
  <id_info>
    <org_study_id>DANAMI-3-PRIMULTI</org_study_id>
    <nct_id>NCT01960933</nct_id>
  </id_info>
  <brief_title>Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization</brief_title>
  <acronym>PRIMULTI</acronym>
  <official_title>Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization A Randomised Comparison of the Clinical Outcome After Complete Revascularisation Versus Treatment of the Infarct-related Artery Only During Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg Universityhospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with ST-elevation myocardial infarction (STEMI) the primary treatment is acute
      angioplasty of the acute occlusion (culprit lesion). In STEMI patients with multi vessel
      disease (MVD) no evidence based treatment of the non-culprit lesions exists. We aim to
      provide evidence as to whether full revascularization or revascularization of the culprit
      lesion only provides the best prognosis for the patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STEMI patients with MVD (30% of total STEMI population) are - following successful primary
      angioplasty - randomized to either no additional percutaneous coronary intervention (PCI) of
      other lesions or full revascularisation guided by fractional flow reserve (FFR).

      Eligible coronary arteries must be &gt;2.0 mm in diameter and at the discretion of the operator
      suitable for PCI. Only arteries with angiographically stenoses &gt; 50% can be randomized. All
      randomized lesions with diameter stenosis &gt; 50% and &lt; 90% are evaluated by FFR and a FFR
      value &lt; 0.80 is considered significant and treated. Stenoses &gt;90% are treated without prior
      FFR.

      Full revascularization is a priori obtained by means of PCI. If, however, PCI is considered
      inferior to coronary artery bypass grafting the latter option can be chosen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>All cause death, myocardial infarction or revascularization</measure>
    <time_frame>48 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Composite of all cause death, myocardial infarction, or ischemia (either subjective or objective)  driven revascularization of non-culprit coronary lesions eligible for and randomized to  either of the two treatment arms at the time of the index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death or myocardial infarction</measure>
    <time_frame>48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for acute coronary syndrome or acute heart failure</measure>
    <time_frame>48 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina status and quality of life</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size in relation to area at risk as determined by MRI</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death, myocardial infarction, repeat revascularisation or occurrence of definite stent thrombosis (according to ARC definition) of non culprit lesions</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wall motion index (WMI) determined by echocardiography</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>ST-elevation Myocardial Infarction.</condition>
  <condition>Multi Vessel Disease.</condition>
  <arm_group>
    <arm_group_label>Culprit lesion revascularization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only the culprit lesion is treated whereas other study lesions are left un-treated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Full revascularization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Culprit lesion is treated initially and all other lesions with diameter stenosis angiographically &gt;50% and FFR &lt;0.80 are treated in a separate procedure within the index hospitalization. Stenoses &gt; 90% are treated without prior FFR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <arm_group_label>Culprit lesion revascularization</arm_group_label>
    <arm_group_label>Full revascularization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FFR</intervention_name>
    <arm_group_label>Full revascularization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Acute onset of chest pain of &lt; 12 hours' duration.

          -  ST-segment elevation ≥ 0.1 millivolt in ≥ 2 contiguous leads, signs of a true
             posterior infarction or documented newly developed left bundle branch block.

          -  Culprit lesion in a major native vessel.

          -  MVD (non-culprit vessels with angiographic stenosis &gt;50%)

          -  Successful primary PCI

        Exclusion Criteria:

          -  Pregnancy.

          -  Known intolerance of acetylsalicylic acid, clopidogrel, heparin or contrast.

          -  Inability to understand information or to provide informed consent.

          -  Haemorrhagic diathesis or known coagulopathy.

          -  Stent thrombosis

          -  Significant left main stem stenosis

          -  Cardiogenic shock at admittance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffen Helqvist, MD, DMSci</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, University of Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Engstrøm, MD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, University of Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henning Kelbæk, MD. DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, University of Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Køber, MD, Prof., DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, University of Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steffen Helqvist, MD, DMSci</last_name>
    <phone>+4535452017</phone>
    <email>steffen.helqvist@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Køber, MD, DMSci</last_name>
    <phone>+4535452017</phone>
    <email>lars.koeber@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Henrik T Hansen, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hans Henrik T Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skejby University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans E Bøtker, MD, DMSci</last_name>
    </contact>
    <investigator>
      <last_name>Hans E Bøtker, MD, DMSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Helqvist, MD, DMSci</last_name>
      <phone>+4535452017</phone>
      <email>steffen.helqvist@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Lene Holmvang, MD, DMSci</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Clemmensen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Jørgensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kari Saunamäki, MD. DMSci</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frants Pedersen, MD, DMSci</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisette Okkels, MD, DMSci</last_name>
    </contact>
    <investigator>
      <last_name>Lisette Okkels, MD, DMSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 14, 2013</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Thomas Engstrom</investigator_full_name>
    <investigator_title>MD, Senior Consultant, DMSCi</investigator_title>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>MVD</keyword>
  <keyword>Full revascularization</keyword>
  <keyword>Culprit lesion revascularization only</keyword>
  <keyword>Primary PCI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
